Strategies for the use of Ginkgo biloba extract, EGb 761® , in the treatment and management of mild cognitive impairment in Asia: Expert consensus.

BACKGROUND: Mild cognitive impairment (MCI) is a neurocognitive state between normal cognitive aging and dementia, with evidence of neuropsychological changes but insufficient functional decline to warrant a diagnosis of dementia. Individuals with MCI are at increased risk for progression to dementia; and an appreciable proportion display neuropsychiatric symptoms (NPS), also a known risk factor for dementia. Cerebrovascular disease (CVD) is thought to be an underdiagnosed contributor to MCI/dementia. The Ginkgo biloba extract, EGb 761® , is increasingly being used for the symptomatic treatment of cognitive disorders with/without CVD, due to its known neuroprotective effects and cerebrovascular benefits. AIMS: To present consensus opinion from the ASian Clinical Expert group on Neurocognitive Disorders (ASCEND) regarding the role of EGb 761® in MCI. MATERIALS & METHODS: The ASCEND Group reconvened in September 2019 to present and critically assess the current evidence on the general management of MCI, including the efficacy and safety of EGb 761® as a treatment option. RESULTS: EGb 761® has demonstrated symptomatic improvement in at least four randomized trials, in terms of cognitive performance, memory, recall and recognition, attention and concentration, anxiety, and NPS. There is also evidence that EGb 761® may help delay progression from MCI to dementia in some individuals. DISCUSSION: EGb 761® is currently recommended in multiple guidelines for the symptomatic treatment of MCI. Due to its beneficial effects on cerebrovascular blood flow, it is reasonable to expect that EGb 761® may benefit MCI patients with underlying CVD. CONCLUSION: As an expert group, we suggest it is clinically appropriate to incorporate EGb 761® as part of the multidomain intervention for MCI.

Comparison of saccade, smooth pursuit and optokinetic nystagmus among Filipino patients diagnosed with schizophrenia, their siblings without schizophrenia and controls using the electronystagmogram: a pilot study at the Santo Tomas Hospital

Objectives: The structural abnormality implicated in schizophrenia was supported by eye movement abnormalities, which were considered biological or trait markers of this psychiatric disorder. We aimed to establish the presence of these changes in schizophrenia by comparing the smooth pursuit eye movement latency, fixed amplitude saccade latency and symmetry of optokinetic nystagmus using the electronystagmogram among Filipino patients diagnosed with schizophrenia, their siblings without schizophrenia and controls who were neither related to the patient nor diagnosed with schizophrenia. Methods: Included were twenty patients 18-40 years old diagnosed of schizophrenia based on the DSM-IV Criteria, their siblings and twenty controls. All subjects underwent electronystagmography at the Ear Center, University of Santo Tomas Hospital where the following were measured: fixed amplitude saccade latency; horizontal smooth pursuit latency and symmetry of optokinetic nystagmus. The values obtained were then analyzed using paired t-test and two way ANOVA. Results: There was a significant difference in the latency of the fixed amplitude saccade and horizontal smooth pursuit among the three groups. PAtients with schizophrenia had the most delayed latency followed by their siblings. No delay was noted in controls. Significant asymmetry of the optokinetic nystagmus in schizophrenic patients was noted. Abnormalities present in the healthy siblings of patients indicated their latent vulnerability towards this disease. Conclusion: The findings of the study further strengthened the anatomical substrate of schizophrenia. These eye movement abnormalities are localized in the parietal and frontal cortex. These are the same areas that are necessary for attentional symmetry, for minimizing distractibility and maintaining the focus of attention on task relevant stimuli which are impaired in patients with schizophrenia.

Prevalence of depression among institutionalized and non-institutionalized Filipino elderly

Objective: To determine if there is a significant difference between the prevalence of depression in institutionalized and non-institutionalized elderly individuals. Methodology: Sixty female individuals 65 years and above were included in the study, thirty from the community while the other thirty reside in an institution for the elderly. The Mini Mental Status Examination was used to establish absence of cognitive impairment in the population, after which the Geriatric Depression Scale was administered. Results: The prevalence of depression in both institutionalized and non-institutionalized elderly individuals was 20 percent. The symptoms of depression in the two groups could be considered as depressive episodes since they were transient and did not result in any deterioration of their function. Conclusion: The finding of this study showed that there was no difference between the prevalence of depression in institutionalized and non-institutionalized elderly individuals.